EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
1.4.4.2 | Stomach Neoplasms |
1152352 |
[Carcinofetal antigens. III. Further carcinofetal antigens (author's transl)] |
causal interaction diagnostic usage unassigned |
3 1 0 |
1.4.4.2 | Arteriovenous Fistula |
17713126 |
[Clinical efficacy of blood flow interruption using the HyperForm in right vertebral arteriovenous fistula--case report] |
therapeutic application unassigned |
3 0 |
1.4.4.2 | Tinnitus |
17713126 |
[Clinical efficacy of blood flow interruption using the HyperForm in right vertebral arteriovenous fistula--case report] |
therapeutic application unassigned |
3 0 |
1.4.4.2 | Carcinoma |
18975570 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma] |
causal interaction diagnostic usage therapeutic application unassigned |
3 3 2 0 |
1.4.4.2 | Intracranial Aneurysm |
11466490 |
[Comparison of MRA and angiography in the follow-up of intracranial aneurysms treated with GDC] |
unassigned |
0 |
1.4.4.2 | Intracranial Aneurysm |
11953184 |
[Computer aided intracranial aneurysm embolization with GDC] |
diagnostic usage ongoing research therapeutic application unassigned |
1 1 1 0 |
1.4.4.2 | Aneurysm |
12063599 |
[Contrast-enhanced intracranial 3 D MR angiography (CE-MRA) in assessing arterial stenoses and aneurysms] |
diagnostic usage unassigned |
2 0 |
1.4.4.2 | Hypertension |
25881457 |
[Correlation study between lupus nephritis patients of rheumatism syndrome and SLEDAI--a clinical study]. |
causal interaction diagnostic usage unassigned |
1 2 0 |
1.4.4.2 | Rheumatic Diseases |
25881457 |
[Correlation study between lupus nephritis patients of rheumatism syndrome and SLEDAI--a clinical study]. |
causal interaction diagnostic usage unassigned |
1 2 0 |
1.4.4.2 | Aneurysm |
9739369 |
[CT angiography to determine the size of intracranial aneurysms before GDC therapy] |
causal interaction diagnostic usage ongoing research therapeutic application |
3 3 1 4 |